冠状病毒研究态势分析

doi:10.13523/j.cb.2002102

中国生物工程杂志

2020, Vol. 40

Issue (1-2): 21-37 DOI: 10.13523/j.cb.2002102

冠状病毒药物研发与技术情报专辑

冠状病毒研究态势分析

巩玥^1,^**(

),廖青云¹,于倩倩¹,史志祥^2,^**(

),陈菁²,张宇辉²,赵光慧²

1 中国科学院文献情报中心北京 100190
2 中国药科大学南京 211198

A Bibliometric Analysis on Coronaviruses

GONG Yue^1,^**(

),LIAO Qing-yun¹,YU Qian-qian¹,SHI Zhi-xiang^2,^**(

),CHEN Jing²,ZHANG Yu-hui²,ZHAO Guang-hui²

1 National Science Library, Chinese Academy of Sciences, Beijing 100190, China
2 China Pharmaceutical University, Nanjing 211198, China

全文: PDF(2936 KB) HTML

摘要：

2019年底,一种新型冠状病毒在武汉引起发热性呼吸道疾病(COVID-19),并在我国境内及周边国家持续蔓延,对人类流行病的防控提出了新的要求。基于文献计量学方法梳理了冠状病毒的研究进展,从全球视角对主要研发国家/地区、核心研究机构和热点研究方向进行了分析,旨在揭示冠状病毒的诊断、预防和治疗的研究态势,以期为当前科研联合攻关提供参考。

关键词： 冠状病毒; 严重急性呼吸综合征; 中东呼吸综合征; 文献计量

Abstract:

In late 2019, a novel coronavirus caused febrile respiratory illness(COVID-19) in Wuhan. The continuous spread of COVID-19 in China and its surrounding countries puts forward a new demand for the prevention and control of this epidemic globally. A bibliometric analysis of the research on coronaviruses has been done in this research, and information related to the main countries, core institutions, key research fields were analyzed, which reveals the current research trends of the diagnosis, prevention and treatment of coronaviruses from a global perspective. The results will provide reference for the current joint research.

Key words: Coronavirus Severe Acute Respiratory Syndrome (SARS) Middle East Respiratory Syndrome (MERS) Bibliometric

收稿日期: 2020-02-20 出版日期: 2020-03-27

ZTFLH:

Q819

通讯作者: 巩玥,史志祥 E-mail: gongy@mail.las.ac.cn;shizhixiangcpu@vip.188.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	巩玥
	廖青云
	于倩倩
	史志祥
	陈菁
	张宇辉
	赵光慧

引用本文:

巩玥,廖青云,于倩倩,史志祥,陈菁,张宇辉,赵光慧. 冠状病毒研究态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 21-37.

GONG Yue,LIAO Qing-yun,YU Qian-qian,SHI Zhi-xiang,CHEN Jing,ZHANG Yu-hui,ZHAO Guang-hui. A Bibliometric Analysis on Coronaviruses. China Biotechnology, 2020, 40(1-2): 21-37.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2002102 或 https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I1-2/21

图1 冠状病毒相关研究的发文年度趋势

表1 冠状病毒研究的TOP10国家/地区

图2 冠状病毒相关研究的国家/地区合作网络

表2 冠状病毒研究的TOP10机构(全球和中国)

图3 冠状病毒的研究主题聚类图谱

图4 SARS相关研究的发文年度趋势

图5 SARS研究的TOP10国家/地区

表3 SARS研究论文发表数量最多的TOP10机构

图6 MERS相关研究的发文年度趋势

图7 MERS 发文量TOP 10国家/地区

图8 MERS相关研究的国家/地区合作网络

表4 MERS研究论文发表数量最多的TOP10机构

表5 冠状病毒诊断研究国家分布

图9 冠状病毒诊断技术研究的国家/地区合作网络

表6 冠状病毒诊断研究TOP10机构(全球和中国)

图10 冠状病毒诊断研究的主题聚类图谱

表7 冠状病毒疫苗研究TOP5国家地区分布

图11 冠状病毒疫苗研究的国家/地区合作网络

表8 冠状病毒疫苗研究机构TOP10(全球和中国)

图12 冠状病毒疫苗研究的主题聚类图谱

表9 冠状病毒抗体研究的TOP5国家/地区分布

图13 冠状病毒抗体研究的国家/地区合作网络

表10 冠状病毒抗体研究的TOP10机构(全球和中国)

图14 冠状病毒抗体研究的自相关图谱

图15 冠状病毒药物研究的发文趋势

表11 冠状病毒药物研究的TOP5国家/地区分布

表12 冠状病毒药物研究的TOP10机构(全球和中国)

图16 冠状病毒药物研究的主题聚类图谱

[1]	Huang C, Wang Y, Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020, doi. org/10.1016/S0140-6736(20)30183-5. doi: org/10.1016/S0140-6736(20)30183-5
[2]	World Health Organization. Novel coronavirus(2019-nCoV) situation report - 22. [2020-02-17]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2.
[3]	Ceraolo C, Giorgi F M . Phylogenomic analysis of the 2019-nCoV coronavirus. Journal of Medical Virology, doi.org/10.1002/jmv.25700. doi: doi.org/10.1002/jmv.25700
[4]	Wong M C, Javornik Cregeen S J, Ajami N J , et al. Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. bioRxiv, 2020, doi.org/10.1101/2020.02.07.939207. doi: doi.org/10.1101/2020.02.07.939207
[5]	Hui D S, I Azhar E, Madani T A , et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis, 2020,91(26):4-6.
[6]	Zhu N, Zhang D, Wang W , et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 2020, DOI: 10.1056/NEJMoa2001017. doi: 10.1056/NEJMoa2001017
[7]	Perlman S . Another decade, Another coronavirus. New England Journal of Medicine, 2020, DOI: 10.1056/NEJMe2001126. doi: 10.1056/NEJMe2001126
[8]	Enserink M . Infectious diseases - WHO wants 21st-century reporting regs. Science, 2003,300(5620):717-7188.
[9]	Brian D A, Baric R S . Coronavirus Genome Structure and Replication. Curr Top Microbiol Immunol, 2005,287:1-30.
[10]	Woo P C Y, Lau S K P, Lam C S F , et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavir. Journal of Virology, 86(7):3995-4008.
[11]	中国疾病预防控制中心. 传染性非典型肺炎防治培训教材. 北京: 中国协和医科大学出版社, 2003.
	Chinese Center for Disease Control and Prevention. Training materials for the prevention and treatment of infectious atypical pneumonia. Beijing: Peking Linion Medical College Press, 2003.
[12]	Wang G S, Deering C, Macke M , et al. Human coronavirus 229E infects polarized airway epithelia from the apical surface. Journal of Virology, 2000,74(19):9234-9239.
[13]	Cleri D J, Ricketti A J, Vernaleo J R . Severe acute respiratory syndrome (SARS). Infectious Disease Clinics of North America, 2010,24(1):175.
[14]	Paules C I, Marston H D, Fauci A S . Coronavirus infections-more than just the common cold. JAMA, 2020, doi: 10.1001/jama.2020.0757. doi: 10.1001/jama.2020.0757
[15]	Arabi Y M, Balkhy H H, Hayden F G , et al. Middle East respiratory syndrome. New England Journal of Medicine, 2017,376(6):584-594.
[16]	Skariyachan S, Challapilli S B, Packirisamy S , et al. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections. Frontiers in Microbiology, 2019, DOI: 10.3389/fmicb.2019.00569. doi: 10.3389/fmicb.2019.00569
[17]	World Health Organization. Emergencies: Novel coronavirus 2019. Geneva:WHO, 2020.
[18]	World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan,China. Geneva:WHO, 2020.
[19]	World Health Organization. A research and development blueprint for action to prevent epidemics. Geneva:WHO, 2018.
[20]	Centers for Disease Control and Prevention. First travel-related case of 2019 novel coronavirus detected in United States CDC press release. Atlanta:CDC, 2020.
[21]	Bhatnagar P K, Das D, Suresh M R . Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). Journal of Pharmacy and Pharmaceutical Sciences, 2008,11(2):1-13.
[22]	Jernigan J A, Low D E, Helfand R F . Combining clinical and epidemiologic features for early recognition of SARS. Emerging Infectious Diseases, 2004,10(2):327-333.
[23]	Chan K H, Poon L, Cheng V C C , et al. Detection of SARS coronavirus in patients with suspected SARS. Emerging Infectious Diseases, 2004,10(2):294-299.
[24]	Peiris J, Poon L . Detection of SARS coronavirus in humans and animals by conventional and quantitative (real time) reverse transcription polymerase chain reactions. Methods Mol Biol, 2008,454:61-72.
[25]	Emery S L, Erdman D D, Bowen M D , et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerging Infectious Diseases, 2004,10(2):311-316.
[26]	Omrani A S, Saad M M, Baig K , et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infectious Diseases, 2014,14(11):1090-1095.
[27]	Widagdo W, Okba N M A, Stalin Raj V , et al. MERS-coronavirus: From discovery to intervention. One Health, 2017,3:11-16.
[28]	Clarivate Analytics. DiseaseBriefing:Coronaviruses. [2020-02-17]. https://clarivate.com/wpcontent/uploads/dlm_uploads/2020/01/coronavirus-report-2.14.2020.pdf.
[29]	Pascal K E, Coleman C M, Mujica A O , et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. PNAS, 112(28):8738-8743.
[30]	李鹤, 谭晓川, 姜栋 , 等. 冠状病毒及其治疗药物研究进展. 中国药学杂志, 2020.[2020-02-17]. http://kns.cnki.net/kcms/detail/11.2162.r.20200212.2010.004.html.
	Li H, Tan X C, Jiang D , et al. Coronavirus and its research progress. Chinese Pharmaceutical Journal, 2020.[2020-02-17]. http://kns.cnki.net/kcms/detail/11.2162.r.20200212.2010.004.html.
[31]	Guan Y . Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science, 302(5643):276-278.
[32]	周浩, 龙北国, 张文炳 , 等. SARS冠状病毒S2基因原核表达及免疫学特性. 中国公共卫生, 2007(08):962-964.
	Zhou H, Long B G, Zhang W B , et al. Prokaryotic expression of SARS-CoV S2 gene and preliminary study on its immune characteristics. Chinese Journal of Public Health, 2007(08):962-964.
[33]	Zhu Z, Chakraborti S, He Y , et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. PNAS, 2007,104(29):12123-12128.
[34]	Ying T, Du L, Ju T W , et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. Journal of Virology, 2014,88(14):7796-7805.
[35]	Ohnuma K, Haagmans B L, Hatano R , et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. Journal of Virology, 2013,87(24):13892-13899.
[36]	Corti D, Zhao J, Pedotti M , et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. PNAS, 112(33):10473-10478.
[37]	Campanale M, Nucera E, Cesario V , et al. OC.04.1: Nickel free-diet enhances helicobacter pylori eradication rate. Digestive and Liver Disease, 2011,43:S125-S6.
[38]	Casadevall A, Pirofski L-A, Racaniello V . The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. Plos Pathogens, 11(4):e1004717.
[39]	Zhou Y, Vedantham P, Lu K , et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research, 2015,116:76-84.
[40]	Millet J K, Whittaker G R . Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Research, 2015,202:120-134.
[41]	Kilianski A, Baker S C . Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. 2014,101(1):105-112.
[42]	Chu, M C . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 59(3):252-256.
[43]	Chan J F-W, Yao Y, Yeung M-L , et al. Treatment with lopinavir/ritonavir or interferon-beta 1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. Journal of Infectious Diseases, 2015,212(12):1904-1913.
[44]	Arabi Y M, Alothman A, Balkhy H H , et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta 1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 2018,19.
[45]	Cinatl J, Morgenstern B, Bauer G , et al. Treatment of SARS with human interferons. Lancet, 2003,362(9380):293-294.
[46]	Tan E L C, Ooi E E, Lin C Y , et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases, 2004,10(4):581-586.
[47]	Stockman L J, Bellamy R, Garner P . SARS: Systematic review of treatment effects. Plos Medicine, 2006,3(9):1525-1531.
[48]	Robinson W E Jr, Mcdougall B R, Essey R A . Inhibition of HIV reverse transcriptase inhibitor- and protease inhibitor-resistant molecular clones of HIV by the biological response modifier, Ampligen. Antiviral Res, 2000,46(1):A48.
[49]	Mitchell W, Blick G, Strayer D , et al. A phase IIB prospective, randomized, controlled study evaluating Ampligen during structured treatment interruption (STI) of HAART in HIV infection. Antiviral Res, 2003,57(3):A41.
[50]	Olsen A L, Morrey J D, Smee D F , et al. Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res, 2007,75(2):104-112.
[51]	Dong S H, Wang X, Tian S C , et al. Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo. Pharmazie, 2018,73(5):269-273.
[52]	Greffex Inc Publication. Texas A&M University System (TAMUS) and Greffex, Inc. sign agreement to collaborate on advanced process and manufacturing development.[2020-02-19]. https://www.greffex.com/texas-am-university-system-tamus-and-greffex-inc-sign-agreement-to-collaborate-on-advanced-process-and-manufacturing-development/.

[1]	贠涛,巩玥,谷芃,徐冰冰,李瑾,赵洗尘. 中国与“一带一路”参与国家抗击新冠肺炎疫情的国际科技合作现状与展望[J]. 中国生物工程杂志, 2021, 41(7): 110-121.
[2]	史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展^*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[3]	张赛,王刚,刘仲明,李辉军,汪大明,钱纯亘. 新型冠状病毒胶体金抗原快速检测试剂的研制及性能评价^*[J]. 中国生物工程杂志, 2021, 41(5): 27-34.
[4]	范月蕾,王跃,王恒哲,李丹丹,毛开云. 新型冠状病毒体外诊断技术研发现状与展望 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 150-161.
[5]	马丽丽,易盼盼,敖妮花,焦洪涛,雷瑞鹏,刘欢. 基于学科类别和富集分析的生物安全研究领域学科交叉研究^*[J]. 中国生物工程杂志, 2021, 41(12): 116-124.
[6]	张赛,向乐,李林海,李辉军,王刚,钱纯亘. 新型冠状病毒(2019-nCoV)IgM /IgG抗体检测试剂的研制及性能评价[J]. 中国生物工程杂志, 2020, 40(8): 1-9.
[7]	白京羽,林晓锋,尹政清. 基于文献计量的全球生物技术研究现状与发展趋势分析[J]. 中国生物工程杂志, 2020, 40(7): 100-109.
[8]	谢华玲,吕璐成,杨艳萍. 全球冠状病毒疫苗专利分析[J]. 中国生物工程杂志, 2020, 40(1-2): 57-64.
[9]	赵萍,杨艳萍. 人冠状病毒感染诊断技术专利态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 51-56.
[10]	李东巧,吕璐成,杨艳萍. 全球人冠状病毒抗体领域研发现状与发展趋势[J]. 中国生物工程杂志, 2020, 40(1-2): 65-70.
[11]	程永庆,刘金毅,林福玉,童梅. 重组人干扰素α1b与新型冠状病毒肺炎防治[J]. 中国生物工程杂志, 2020, 40(1-2): 71-77.
[12]	林福玉,刘金毅,程永庆. 重组人干扰素α1b抗新型冠状病毒的基础和临床研究进展[J]. 中国生物工程杂志, 2020, 40(12): 1-7.
[13]	王国强,于茵茵,曾华辉,王旭东,吴玉彬,尚立芝,李玉林,张怡青,张西西,张振强,王云龙. 基于MS2噬菌体病毒样颗粒的RT-PCR检测新型冠状病毒(SARS-CoV-2)质控品制备^*[J]. 中国生物工程杂志, 2020, 40(12): 31-40.
[14]	陈利军,屈晶晶,项春生. 间充质干细胞在2019新型冠状病毒肺炎(COVID-19)中的治疗潜能、临床研究与应用前景^*[J]. 中国生物工程杂志, 2020, 40(11): 43-55.
[15]	程子昭,陈楚楚,应磊,李校堃,黄志锋. 冠状病毒基因组特征及感染特点比较^*[J]. 中国生物工程杂志, 2020, 40(11): 56-66.

Viewed

Full text

Abstract

Cited

Shared

Discussed